期刊
TRANSPLANTATION
卷 89, 期 11, 页码 1336-1340出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/TP.0b013e3181d98c3d
关键词
Bismuth-213; Anti-CD45 mAb; Haploidentical transplantation; Nonmyeloablative transplantation
资金
- National Institutes of Health [HL36444, CA118940]
- Graduate School of Medicine, Osaka City University, Osaka, Japan
- FAPESP, Brazil
- Department of Health and Human Services, NIH, Bethesda, MD
Background. A pilot study was conducted to determine whether conditioning using selective targeting of hematopoietic cells with an alpha-particle emitter, bismuth-213 (Bi-213)-labeled anti-CD45 monoclonal antibody (mAb) is sufficient to overcome the major histocompatibility barrier in a canine model of dog leukocyte antigen-haploidentical hematopoietic cell transplantation (HCT). Methods. Six dogs were administered 0.5 mg/kg Bi-213-labeled anti-CD45 mAb (dose Bi-213 = 2.26-4.9 mCi/kg) in six to eight injections. For postgrafting immunosuppression, all dogs received cyclosporine and mycophenolate mofetil. Results. All dogs had initial donor engraftment, with three of six dogs having sustained engraftment to last point of follow-up. Two dogs receiving 2.26 and 3.25 mCi/kg of Bi-213 rejected their grafts at day +127 and +125, respectively, whereas dogs receiving Bi-213 doses of 3.3 mCi/kg or greater achieved high level donor chimerism. Conclusion. The results suggest that nonmyeloablative conditioning with Bi-213-labeled anti-CD45 mAb could be applicable to major histocompatibility haploidentical HCT without excessive nonhematologic regimen-related toxicity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据